Partnering

One platform. Six ways to work with us.

PharmaTher brings formulation science, validated formulations, regulatory experience and exclusive North American access to CraftMake™. Starting takes one conversation.

Start a partnering conversation Get the partnering overview

Two print heads printing dual-print tablets

Choose how you want to work with us.

1 · Place

Bring 3D printing in-house

CraftMake™ systems, software, materials, training, validation and service, with validated formulations from day one.

Suits: 503A/503B pharmacies, hospitals, CDMOs, labs, government sites

Start on M3DICINES ↗

2 · License

License M3DICINES™ formulations

Validated formulations for personalized doses, combinations and controlled release.

Suits: pharmacies, telehealth platforms, pharma

Start on M3DICINES ↗

3 · Sell

White-label products

Pharma, peptide and nutraceutical products under your own brand, fulfilled through our Center of Excellence.

Suits: telehealth and consumer-health brands

Talk to us →

4 · Develop

3D-printed CDMO services

Formulation, clinical trial supply and small-batch manufacturing through our GMP partner.

Suits: pharma and biotech, including virtual biotechs

Start on M3DICINES ↗

5 · Discover

Research collaborations

Feasibility and formulation science, and funded programs.

Suits: universities, hospitals, government labs, pharma R&D

Propose a collaboration →

6 · Prepare

National emergency readiness

Qualified printer nodes that make countermeasures on demand, under one quality system.

Suits: ASPR, BARDA, DRDC, DoD/DHA, provinces, hospitals

Request a capability briefing →

Who we work with

503A and 503B pharmaciesPlacements, formulations, white-label supply

Telehealth and consumer healthWhite-label products, a manufacturing layer

CDMOs, pharma and biotechClinical supply, specialty production, licensing

Hospitals and health systemsPediatric and special-population doses

Academic and research labsFeasibility and formulation science

Government and defencePreparedness nodes and countermeasures

Strategic assets

Assets available to license, sell, partner or spin out.

All strategic assets →

KetaVault™CMC package, INDs, protocols and five orphan designations.

Ketamine patchMicroneedle patch; IND-enabling study complete; Phase 1-ready.

KetaMist®Needle-free, patient-controlled ketamine; collaboration toward an FDA pathway.

Sairiyo Therapeutics49% stake in a company developing oral cepharanthine.

Request a non-confidential summary

Start a partnering conversation

Tell us a little about you. We'll send the partnering overview by email and reply within two business days.

Looking for a printer or contract manufacturing? Go to M3DICINES ↗

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form.